[Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer].
Larbouret
Christel
C
Robert
Bruno
B
Teulon
Isabelle
I
Azria
David
D
Pèlegrin
André
A
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019281:Dimerization; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D000077544:Panitumumab; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000276:immunology; D000068878:Trastuzumab; D023041:Xenograft Model Antitumor Assays
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D009363:Neoplasm Proteins; D000077544:Panitumumab; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C512478:EGFR protein, human; C485206:pertuzumab; C520777:matuzumab